| |
|
|
|
|
|
 |
| |
|
±×·¡Ä®¿¬Áúݼ¿ GRECAL SOFT CAP.[Calcium Carbonate , Cholecalciferol]
|
|
ÀϹÝÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
643902310[A05002011]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ݼ¿(2006.11.01)(ÇöÀç¾à°¡)
\74 ¿ø/1ݼ¿(2002.08.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
À¯¹é»öÀÇ Á¡Á¶ÇÑ Çöʹ°ÁúÀÌ ÃæÀüµÈ Ÿ¿øÇüÀÇ ÁÖȲ»ö ¿¬Áúݼ¿ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
90ݼ¿ |
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
1. ´ÙÀ½°æ¿ìÀÇ ºñŸ¹Î DÀÇ º¸±Þ
- ÀÓ½Å․¼öÀ¯±â
- ¹ßÀ°±â
- ³ë³â±â
2. ÀÌ ¾à¿¡ ÇÔÀ¯µÈ ºñŸ¹Î µîÀÇ È¿´É․È¿°ú´Â ´ÙÀ½°ú °°´Ù.
• ºñŸ¹ÎD(³óÃàÄÝ·¹Ä®½ÃÆä·Ñ)
- »À, ÀÌÀÇ ¹ßÀ°ºÒ·®
- ±¸·çº´ÀÇ ¿¹¹æ
3. Ä®½·°áÇÌ ¹× ±âŸ Ä®½·ÀÇ º¸±Þ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¸¸ 12¼¼ÀÌ»ó ¹× ¼ºÀÎ : 1ȸ 2ĸ½¶¾¿ 1ÀÏ 1~2ȸ º¹¿ëÇÑ´Ù.
|
| ±Ý±â |
1) °úÄ®½·Ç÷Áõ(hypercalciumia : Ç÷¾× Áß¿¡ Ä®½·ÀÌ °úÀ×À¸·Î Á¸ÀçÇÏ´Â »ó ÅÂ)ȯÀÚ, À¯À°Á¤¿ë, ½ÅÁúȯ ȯÀÚ
2) ÀÌ ¾à ¹× ÀÌ ¾à¿¡ Æ÷ÇÔµÈ ¼ººÐ¿¡ °ú¹ÎÁõÀÌ Àִ ȯÀÚ
3) 12°³¿ù ¹Ì¸¸ÀÇ ¿µ¾Æ
4) ½Å°á¼® ȯÀÚ
5) ÁßÁõÀÇ ½ÅºÎÀü ȯÀÚ
6) ´ëµÎÀ¯¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ
7) Äá ¶Ç´Â ¶¥Äá¿¡ °ú¹ÎÁõÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
1) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
2) ÇÞºûÀ» ¸¹ÀÌ º¸°í Á¤»óÀûÀÎ ½Ä»ç¸¦ ÇÏ´Â ¾î¸°ÀÌ
3) ÀӺΠ¹× ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º, ¼öÀ¯ºÎ, ¹Ì¼÷¾Æ, À¯¾Æ
¨ç ºñŸ¹Î D´Â ¸ðÀ¯·Î ºÐºñµÇ¾î ½Å»ý¾Æ¿¡°Ô °íÄ®½·Ç÷ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù
4) ½ÉÀå․¼øÈ¯±â°è±â´É Àå¾Ö ȯÀÚ
5) ½ÅÀåÀå¾Ö ȯÀÚ
6) Àú´Ü¹éÇ÷Áõ ȯÀÚ
7) °½É¹è´çü¸¦ Åõ¿© ÁßÀΠȯÀÚ
8) ½ÅÀå°á¼® º´·ÂÀÌ Àִ ȯÀÚ
9) °íÁö´Ü¹éÇ÷Áõ, ´ç´¢º´¼º°íÁöÁúÇ÷Áõ ¹× ÃéÀå¿° µî Áö¹æ´ë»ç ÀÌ»ó ȯÀÚ ¶Ç´Â ÁöÁú¼º À¯Á¦¸¦ ½ÅÁßÈ÷ Åõ¿©ÇØ¾ß Çϴ ȯÀÚ
10) ÀÌ ¾àÀº Ȳ»ö5È£(¼±¼Â¿»·Î¿ì FCF, Sunset Yellow FCF)¸¦ ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. |
| ÀÌ»ó¹ÝÀÀ |
´ÙÀ½°ú °°Àº °æ¿ì ÀÌ ¾àÀÇ º¹¿ëÀ» Áï°¢ ÁßÁöÇϰí ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í. »ó´ã ½Ã °¡´ÉÇÑ ÇÑ ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í
1) ÀÌ ¾àÀÇ Åõ¿©¿¡ ÀÇÇÏ¿© ´ÙÀ½ÀÇ Áõ»óÀÌ ÀÖÀ» °æ¿ì.
- ±¸¿ª, ±¸Åä, ¼³»ç, º¯ºñ, ÀúÇ÷¾Ð, ¾ó±¼´Þ¾Æ¿À¸§, ½É¹Úµ¿ºÒ±ÔÄ¢, ÇǺιßÁø
2) ´ë·®Åõ¿©·Î ÀÎÇØ ±¸¿ª, ±¸Åä µîÀÇ À§ÀåÁõ»ó, °í³ªÆ®·ýÇ÷Áõ, ¿ïÇ÷½ÉºÎÀü, ºÎÁ¾(ºÎ±â) µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) Àå±âÅõ¿©¿¡ ÀÇÇØ °íÄ®½·Ç÷Áõ ¹× °á¼®ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) Ç׾˵µ½ºÅ×·ÐÁ¦, Æ®¸®¾ÏÅ×·»°ú º´¿ëÅõ¿©½Ã °íÄ®·ýÇ÷ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÒ °Í
5) ¿ì¹ßÀûÀ¸·Î °ú·®º¹¿ë ÇÑ °æ¿ì
6) 1°³¿ù Á¤µµ º¹¿ëÇÏ¿©µµ Áõ»óÀÇ °³¼±ÀÌ ¾øÀ» °æ¿ì
|
| »óÈ£ÀÛ¿ë |
ÀÌ ¾àÀ» º¹¿ëÇÏ´Â µ¿¾È ´ÙÀ½ÀÇ ¾àÀ» º¹¿ëÇÏÁö ¸» °Í.
1) Àλ꿰, Ä®½·¿°, °æ±¸¿ë Åׯ®¶ó»çÀÌŬ¸°°è Á¦Á¦, Á¦»êÁ¦ |
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: CHOLECALCIFEROLCERNEVIT-12 (ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A)
FOSAMAX PLUS D (ALENDRONATE SODIUM; CHOLECALCIFEROL)
INFUVITE ADULT (ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K)
INFUVITE PEDIATRIC (ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K)
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE) (ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K)
±âÁØ ¼ººÐ: CALCIUM CARBONATEACTONEL WITH CALCIUM (COPACKAGED) (CALCIUM CARBONATE; RISEDRONATE SODIUM)
CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE (CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE)
PEPCID COMPLETE (CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Calcium¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Calcium¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. More than 500 human proteins are known to bind or transport calcium. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Parathyroid hormone (secreted from the parathyroid gland) regulates the resorption of Ca2+ from bone. Calcitonin stimulates incorporation of calcium in bone, although this process is largely independent of calcitonin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. The currently recommended calcium intake is 1,500 milligrams per day for women not taking estrogen and 800 milligrams per day for women on estrogen. There is close to 300 milligrams of calcium in one cup of fluid milk. Calcium carbonate is currently the best and least expensive form of calcium supplement available.
Cholecalciferol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The first step involved in the activation of vitamin D3 is a 25-hydroxylation which is catalysed by the 25-hydroxylase in the liver and then by other enzymes. The mitochondrial sterol 27-hydroxylase catalyses the first reaction in the oxidation of the side chain of sterol intermediates. The active form of vitamin D3 (calcitriol) binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
|
| Pharmacology |
Cholecalciferol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cholecalciferol (vitamin D3) is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.
|
| Metabolism |
Cholecalciferol¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 24A1 (CYP24A1)Cytochrome P450 11A1 (CYP11A1)
|
| Protein Binding |
Cholecalciferol¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 50% to 80%
|
| Half-life |
Cholecalciferol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Several weeks
|
| Absorption |
Cholecalciferol¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed
|
| Pharmacokinetics |
Calcium CarbonateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : À§Àå°üÀ» ÅëÇØ ÀÌ¿ÂÈ ÇüÅ·ΠÈí¼öµÇ¸ç ºñŸ¹Î D°¡ ÇÊ¿ä;»ê¼º¿¡¼ Èí¼öÁõ°¡
- »ýü³»ÀÌ¿ë·ü : 4-45 %
- À½½Ä¹°ÀÇ ¿µÇâ : Ä®½·Èí¼ö(10-30 %)Áõ°¡
¼¶À¯¼Ò°¡ ¸¹Àº À½½ÄÀº À§Àå°ü ¹èÃâ½Ã°£À» Áöü½ÃÄÑ Ä®½·Èí¼ö¸¦ ÀúÇϽÃÅ´
- ºÐÆ÷ : ŹÝÅë°ú; À¯ÁóºÐºñ
- ´Ü¹é°áÇÕ : 45 %
- ¼Ò½Ç : Èí¼öµÇÁö ¾ÊÀº Ä®½·Àº ÁÖ·Î º¯À¸·Î ¹è¼³
½Å¹è¼³ : 20 % (50-300 mg/day)
CholecalciferolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : À§Àå°üÀ¸·ÎºÎÅÍ Àß Èí¼öµÈ´Ù.
- ºÐÆ÷ : Èí¼ö ÈÄ chylomicronsÀ» ÅëÇØ Ç÷ÁßÀ¸·Î ¼ö¼ÛµÇ¸ç, ÁÖ·Î °£¿¡ ÀúÀåµÇ°í ±âŸ Áö¹æ, ±ÙÀ°, ÇǺΠ¹× °ñ Á¶Á÷ µî¿¡µµ Á¸ÀçÇÑ´Ù.
- ´Ü¹é°áÇÕ : ÁÖ·Î vitamin D-binding ¥á-globulin¿¡ °áÇÕÇϸç albumin°úµµ °áÇÕÇÑ´Ù.
- ´ë»ç : °£¿¡¼ vitamin D 25-hydroxylase¿¡ ÀÇÇØ 25-[OH] D·Î ´ë»çµÈ ÈÄ, ½ÅÀå¿¡¼ vitamin D 1-hydroxylase¿¡ ÀÇÇØ Ȱ¼ºÇüÀÎ 1,25-[OH]2 D·Î ´ë»çµÈ´Ù.
- ¹Ý°¨±â : vitamin D : Ç÷Àå ³»¿¡¼ 19-25 ½Ã°£
- ¼Ò½Ç : ÁÖ·Î ´ãÁó ¹× ´ëº¯À» ÅëÇØ ¹è¼³µÇ¸ç ¼Ò·®Àº ´¢¸¦ ÅëÇØ ¹è¼³µÈ´Ù.
|
| Biotransformation |
Cholecalciferol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Within the liver, cholecalciferal is hydroxylated to calcidiol (25-hydroxycholecalciferol) by the enzyme 25-hydroxylase. Within the kidney, calcidiol serves as a substrate for 1-alpha-hydroxylase, yielding calcitriol (1,25-dihydroxycholecalciferol), the biologically active form of vitamin D3.
|
| Toxicity |
Cholecalciferol¿¡ ´ëÇÑ Toxicity Á¤º¸ Hypercalcemia - Early symptoms of hypercalcemia, include nausea and vomiting, weakness, headache, somnolence, dry mouth, constipation, metallic taste, muscle pain and bone pain. Late symptoms and signs of hypercalcemia, include polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis, pancreatitis, photophobia, rhinorrhea, pruritis, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated ALT (SGPT) and AST (SGOT), ectopic calcification, nephrocalcinosis, hypertension and cardiac arrhythmias.
|
| Drug Interactions |
Calcium¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate Formation of non-absorbable complexesAmprenavir The antiacid decreases the absorption of amprenavirAtazanavir This gastric pH modifier decreases the levels/effects of atazanavirChloroquine The antiacid decreases the absorption of chloroquineCiprofloxacin Formation of non-absorbable complexesDapsone Formation of non-absorbable complexesDelavirdine The antiacid decreases the effect of delavirdineDemeclocycline Formation of non-absorbable complexesDoxycycline Formation of non-absorbable complexesEnoxacin Formation of non-absorbable complexesFosamprenavir The antiacid decreases the absorption of amprenavirGrepafloxacin Formation of non-absorbable complexesIbandronate Formation of non-absorbable complexesIndinavir The antiacid decreases the absorption of indinavirItraconazole The antacid decreases the effect of the imidazoleKetoconazole The antacid decreases the effect of the imidazoleLevofloxacin Formation of non-absorbable complexesLevothyroxine Calcium decreases absorption of levothyroxineLomefloxacin Formation of non-absorbable complexesMethacycline Formation of non-absorbable complexesMinocycline Formation of non-absorbable complexesMoxifloxacin Formation of non-absorbable complexesNorfloxacin Formation of non-absorbable complexesOfloxacin Formation of non-absorbable complexesOxytetracycline Formation of non-absorbable complexesPefloxacin Formation of non-absorbable complexesPolystyrene sulfonate Formation of non-absorbable complexesRisedronate Formation of non-absorbable complexesTetracycline Formation of non-absorbable complexesTrovafloxacin Formation of non-absorbable complexesClodronate Formation of non-absorbable complexesEtidronic acid Formation of non-absorbable complexesMycophenolate mofetil Formation of non-absorbable complexesTemafloxacin Formation of non-absorbable complexes
Cholecalciferol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Calcium¿¡ ´ëÇÑ Description Á¤º¸ Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast.
Cholecalciferol¿¡ ´ëÇÑ Description Á¤º¸ Derivative of 7-dehydroxycholesterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from ergocalciferol in having a single bond between C22 and C23 and lacking a methyl group at C24. [PubChem]
|
| Dosage Form |
Calcium¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralLiquid DentalLiquid IntravenousLiquid OralLiquid SublingualPaste DentalPowder OralPowder, for solution OralSolution IntramuscularSolution IntravenousSolution OralSolution / drops OralSyrup OralTablet OralTablet, chewable Oral
Cholecalciferol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralTablet Oral
|
| Drug Category |
Cholecalciferol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihypocalcemic AgentsAntihypoparathyroid AgentsBone Density Conservation AgentsEssential VitaminVitaminsVitamins (Vitamin D)
|
| Smiles String Canonical |
Calcium¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ Not Available
Cholecalciferol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)CCCC(C)C1CCC2C(CCCC12C)=CC=C1CC(O)CCC1=C
|
| Smiles String Isomeric |
Calcium¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ Not Available
Cholecalciferol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)CCC1=C
|
| InChI Identifier |
Calcium¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ Not Available
Cholecalciferol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/t21-,24+,25-,26+,27-/m1/s1
|
| Chemical IUPAC Name |
Calcium¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
Cholecalciferol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1S)-3-[2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-02-15
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|